Announcement on the Company's 2019 Daily Related Transactions
Release time:
2020-08-05
证券简称:尖峰集团 证券代码:600668 编号:临2019-011
债券简称:13尖峰02 债券代码:122344
浙江尖峰集团股份有限公司
关于公司2019年度日常关联交易的公告
本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏,并对其内容的真实性、准确性和完整性承担个别及连带责任。
重要内容提示:
l 浙江尖峰集团股份有限公司及控股子公司(以下简称“本公司”)预计 2019 年与本公司联营企业天士力控股集团有限公司及其控股子公司(以下简称“天士力集团”)发生采购、销售等日常关联交易,交易金额合计预计不超过人民币2290万元。
l 本次日常关联交易系本集团日常经营业务中发生的持续性关联交易,遵守“公平、公正、公开”的市场交易原则,不会影响公司独立性,不会对公司的财务状况、经营成果产生不利影响,不会损害本公司或中小股东的利益。
一、日常关联交易基本情况
(一)日常关联交易履行的审议程序
根据公司经营需要,2019年本公司预计与天士力集团发生采购、销售等日常关联交易,上述日常关联交易合计发生额度在本公司2018年底经审计净资产的0.5%到5%之间,根据上海证券交易《股票上市规则》及公司《章程》的规定,该关联交易事项需提交董事会审议,但不需提交股东大会审议。
2019年4月26日,公司召开了第十届董事会第10次会议,公司现有九名董事,其中八名董事亲自参加了会议,杜自弘董事委托蒋晓萌董事代为出席会议并表决,根据《上海证券交易所股票上市规则》的规定,本公司董事会就上述议案进行表决时,关联董事蒋晓萌先生、虞建红先生、杜自弘先生回避了该议案的表决。经审议与表决,董事会以6票同意、0票反对、0票弃权审议通过了《关于公司2019年度日常关联交易的议案》。
公司独立董事事前对该事项进行了审议,同意将该议案提交给公司第十届董事会第10次会议审议,并对董事会通过该议案发表了同意的独立意见,认为:该项关联交易遵守“公平、公正、公开”的市场交易原则,以招标价或以医疗机构中标价为基准协商确定交易价格,交易金额占公司总销售、采购的比例较小,不会影响本公司独立性,不会对本公司的财务状况、经营成果产生不利影响,未发现有损害公司及中小股东权益的情形。同意公司2019年度相关日常关联交易事项。
(二)预计日常关联交易金额 单位:万元
|
交易内容 |
2019年预计金额 |
2019年已发生额 |
2018年发生额(不含税) |
占总销售、采购金额的比例(%) |
|
向关联人购买商品 |
1550.00 |
90.95 |
712.64 |
0.36 |
|
向关联人销售商品 |
740.00 |
193.68 |
542.88 |
0.16 |
|
合计 |
2290.00 |
284.63 |
1255.52 |
|
二、关联方介绍和关联关系
(一)关联方的基本情况。
天士力控股集团有限公司,成立于2000年3月30日,公司住所为天津北辰科技园区,法定代表人为闫希军,公司注册资本为34358.90万元人民币。公司经营范围:对外投资、控股;天然植物药种植及相关加工、分离;组织所属企业开展产品的生产、科研、销售、进出口经营业务;各类商品、物资的批发、零售;技术开发、咨询、服务、转让生物技术(不含药品生产与销售)及产品;自有设备、房屋的租赁;各类经济信息咨询;本企业研制开发的技术和生产的科研产品的出口业务;本企业科研和生产所需的技术、原辅材料、机械设备、仪器仪表、零配件的进口业务;本企业的进料加工和“三来一补”业务;矿业开发经营;原料药(盐酸非索非那定、右佐匹克隆)生产;因特网信息服务(除新闻、出版、教育、医疗器械和电子公告以外的信息服务内容,业务覆盖范围:天津市);会议及展览服务;游览景区管理;旅游管理服务;旅游信息咨询服务;门票销售与讲解服务;旅游商品、纪念品开发与销售。(以上经营范围内国家有专营专项规定的按规定办理)。(依法须经批准的项目,经相关部门批准后方可开展经营活动)
截至2018年12月31日该公司总资产409.46亿元,归属于母公司股东净资产54.50亿元,2018年实现营业收入197.97亿元,归属于母公司股东净利润2.92亿元。
(二)与上市公司的关联关系
本公司持有天士力集团20.76%的股权,且本公司董事蒋晓萌先生、虞建红先生兼任天士力集团的董事,本公司董事杜自弘先生曾担任天士力集团的董事(卸任未满12个月),根据《上海证券交易所股票上市规则》及其他相关规定,天士力集团及其控股子公司为本公司的关联人,本项交易为关联交易。
|
关联方名称 |
关联关系 |
|
天士力控股集团有限公司 |
本公司董事兼任该公司董事 |
|
天津天士力现代中药资源有限公司 |
天士力集团控制的下属公司,与天士力集团共同构成同一关联人。 |
|
重庆国清中药材有限公司 |
|
|
江苏天士力帝益药业有限公司 |
|
|
天津天士力医药商业有限公司 |
|
|
辽宁天士力医药有限公司 |
|
|
陕西天士力医药有限公司 |
|
|
天士力(佛山)医药有限公司 |
|
|
天士力(汕头)医药有限公司 |
(三)前期同类关联交易的执行情况和履约能力分析
2018年,公司与天士力集团之间发生的关联交易总额为1255.52万元(不含税),其中:采购商品712.64万元,占公司采购金额的0.36%;销售商品542.88万元,占公司销售的0.16%。该交易占同类交易金额的比例很小,不影响本公司的独立性。各关联方均依法存续且生产经营正常,经济效益和财务状况良好,履约能力强,不会给交易双方的交易行为带来风险。
三、关联交易主要内容和定价政策
(一)关联交易主要内容
本公司拟在2019年度继续向天士力集团采购复方丹参滴丸、养血清脑丸、水飞蓟宾胶囊、替莫唑胺胶囊、右佐匹克隆片等产品,并继续向其销售力斯得、帕罗西汀、玻璃酸钠滴眼液、醋氯芬酸缓释片、注射用盐酸头孢甲肟、延胡索、生半夏等产品。
(二)定价政策
公司与关联方的交易本着公平、公正、公开的市场交易原则,交易价格主要以招标价或以医疗机构中标价为基准协商确定。
四、关联交易目的和对上市公司的影响
本次关联交易系本公司日常经营业务中发生的持续性关联交易,有利于发挥双方的产品优势和销售、采购的网络优势,实现优势互补和资源合理配置,提升营销能力,增加销售收入。同时,天士力集团为本公司的联营企业,本公司持有其20.76%的股权,该公司及其控股子公司的收入增加、效益提升有利于本公司的业绩增长。
上述交易遵守“公平、公正、公开”的市场交易原则,以招标价或以医疗机构中标价为基准协商确定交易价格,交易金额占销售、采购的比例较小,不会影响本公司独立性,不会对本公司的财务状况、经营成果产生不利影响,不会损害本公司或中小股东的利益。
特此公告
l 报备文件
(一)公司第十届董事会第10次会议决议;
(二)第九届监事会第6次会议决议;
(三)独立董事的独立意见
(四)独立董事关于公司关联交易事前认可声明
特此公告。
浙江尖峰集团股份有限公司
董事会
二〇一九年四月三十日
More information
The company was rated as an advanced unit of the city's focus on talent and love talent.
News from our newspaper On December 11, the Talent Work Leading Group of the Jinhua Municipal Committee of the Communist Party of China commended the advanced units of Jinhua City that value talents and love talents. 36 units including Jianfeng Group won this honor. The selection of advanced units that value talents and love talents is a measure taken by the Jinhua Municipal Party Committee to further create a good atmosphere of focusing on talents and loving talents, fully respect and make good use of the first resource of talents, serve innovation to drive development, and implement the development strategy of strengthening the province with talents and innovation. The enterprises and institutions that have won this honorary title have always regarded talents as the fundamental driving force for development for a long time, regarded the investment of talents as the most effective investment, and integrated the love of talents into the unit culture. Remarkable achievements have been made in gathering talents, achieving talents, transforming and upgrading, and accelerating development. The Jinhua Municipal Party Committee requires the majority of employers to learn from advanced units, vigorously promote the trend of focusing on talents and loving talents, remove the obstacles to the talent development system and mechanism, and in accordance with the requirements of "walking in the forefront and jointly building Jinhua", in order to promote the construction of a modern metropolitan area and accelerate the construction of the province An important growth pole for high-quality development provides talent support and intellectual guarantee. (this newspaper reporter)
2020
07-31
The company was rated as an advanced unit of the city's focus on talent and love talent.
News from our newspaper On December 11, the Talent Work Leading Group of the Jinhua Municipal Committee of the Communist Party of China commended the advanced units of Jinhua City that value talents and love talents. 36 units including Jianfeng Group won this honor. The selection of advanced units that value talents and love talents is a measure taken by the Jinhua Municipal Party Committee to further create a good atmosphere of focusing on talents and loving talents, fully respect and make good use of the first resource of talents, serve innovation to drive development, and implement the development strategy of strengthening the province with talents and innovation. The enterprises and institutions that have won this honorary title have always regarded talents as the fundamental driving force for development for a long time, regarded the investment of talents as the most effective investment, and integrated the love of talents into the unit culture. Remarkable achievements have been made in gathering talents, achieving talents, transforming and upgrading, and accelerating development. The Jinhua Municipal Party Committee requires the majority of employers to learn from advanced units, vigorously promote the trend of focusing on talents and loving talents, remove the obstacles to the talent development system and mechanism, and in accordance with the requirements of "walking in the forefront and jointly building Jinhua", in order to promote the construction of a modern metropolitan area and accelerate the construction of the province An important growth pole for high-quality development provides talent support and intellectual guarantee. (this newspaper reporter)
2020
07-30
Peak Pharmaceutical Becomes National Intellectual Property Demonstration Enterprise
Just one year after it was identified as a national intellectual property advantage enterprise in 2016, "Zhejiang Jianfeng Pharmaceutical Co., Ltd." appeared in the list of national intellectual property demonstration enterprises in 2017 recently announced by the State Intellectual Property Office. As a result, Jianfeng Pharmaceutical has become the first and only national intellectual property demonstration enterprise in Jinhua City. On December 12, the State Intellectual Property Office issued a notice to announce the list of national intellectual property demonstration enterprises and advantageous enterprises in 2017. After the enterprise declaration, the recommendation of the provincial and municipal bureaus, the review of the national bureau, and the public announcement, 182 national intellectual property demonstration enterprises and 816 national intellectual property advantage enterprises have been identified. Including Jianfeng Pharmaceutical, Zhejiang Province has been identified as only 15 national intellectual property demonstration enterprises. With the continuous development of enterprises in recent years, Jianfeng Pharmaceutical has set up a special working organization to cultivate and improve the intellectual property ability from the aspects of strategic management, creation, operation and protection of intellectual property rights. It has successively compiled and implemented 27 procedural documents and 36 forms such as "Intellectual Property Management Manual", "Intellectual Property Reward and Punishment System" and "Trade Secret Management System, and timely according to the policy, the current situation of the enterprise to revise, in order to ensure the compliance and effectiveness of the operation of the system. In 2012 and 2013, Jianfeng Pharmaceutical was successively rated as a patent demonstration enterprise in Jinhua City and Zhejiang Province; in 2013, it won the third prize of Jinhua Patent Implementation Award; in 2016, it passed the certification of intellectual property management system and was identified as a national intellectual property advantage enterprise. Currently, Peak Pharmaceuticals has
2020
07-31
Jianfeng Pharmaceutical Approved to Set up Provincial Research Institute
A few days ago, the relevant departments of Zhejiang Province approved the establishment of the provincial research institute of the peak pharmaceutical company. This is another honor won by Jianfeng Pharmaceutical in the field of independent research and development and scientific and technological innovation after the national postdoctoral research workstation and Zhejiang academician expert workstation. The provincial enterprise research institute is a high-level R & D institution led by the Provincial Department of Science and Technology, jointly recognized by the Provincial Economic and Information Commission and the Provincial Development and Reform Commission. As an important part of the national technological innovation system, the Enterprise Research Institute is the core force of the innovation-driven development of Jianfeng Pharmaceutical, which reflects the ability of Jianfeng Pharmaceutical to set up higher-level and higher-level R & D institutions on its own. the ability to gather and integrate innovation elements, organize scientific and technological innovation, support the sustainable development of enterprises, and lead the technological progress of the industry. As a pharmaceutical enterprise, scientific and technological innovation is the eternal theme of enterprise development, and talent is the key to scientific and technological innovation. Over the years, Jianfeng Pharmaceutical has not only focused on cultivating its own scientific research talents, but also established close cooperative relations with well-known universities and scientific research institutions such as China Pharmaceutical University, Shenyang Pharmaceutical University, Sichuan Antibiotic Industry Research Institute, and also focused on introducing top think tanks. In 2011, Professor Liu Jiajian and his team from Sichuan Institute of Antibiotic Industry were introduced, focusing on the technical research of key intermediates of methoxy cephalosporin. In 2013, Professor Shan Weiguang and his scientific research team from Zhejiang University of Technology were introduced to carry out research on preparation technology. In 2015, Professor Wang Guangji, academician of the Chinese Academy of Engineering, was hired as the chief scientist to organize the research on the anti-drug resistance mechanism of national class I new drugs by intracellular pharmacokinetics. In 2017 with Shanghai antibody
2020
07-31
On November 16, the company held the first extraordinary general meeting of shareholders in 2017, which deliberated and passed the proposal on the expiration of the term of the board of directors and the proposal on the expiration of the term of the board of supervisors, and elected a new board of directors and the board of supervisors. The meeting used a combination of on-site registered voting and online voting to vote on director candidates one by one, and elected Jiang Xiaomeng, Du Zihong, Yu Jianhong, Huang Sujian, Liu Bo, Zhang Guoping, Huang Conyun, Sun Hongbin, and Shi Ximin as the company's tenth board of directors. Directors, of which Huang Conyun, Sun Hongbin, and Shi Ximin are independent directors. The meeting used a combination of on-site registered voting and online voting to vote on supervisor candidates one by one, and elected Chen Tianci, Lu Ruimei, and Shi Fu as supervisors of the company's ninth board of supervisors. Prior to this, the company's trade union held an enlarged meeting of the trade union committee to elect Qin Xuping and Jin Huazhong as employee representative supervisors of the ninth board of supervisors. On the same day, the company's tenth board of directors held its first meeting and elected Jiang Xiaomeng as the chairman of the tenth board of directors. Jiang Xiaomeng, Du Zihong, Huang Sujian, Sun Hongbin and Shi Ximin were elected as members of the Strategy Committee of the 10th Board of Directors, and Jiang Xiaomeng was the chairman of the Strategy Committee. Shi Ximin, Huang Conyun and Jiang Xiaomeng were elected as members of the audit committee of the 10th board of directors, and Shi Ximin was the chairman. Sun Hongbin, Huang Conyun and Jiang Xiaomeng were elected as members of the nomination committee of the 10th board of directors, and Sun Hongbin was the chairman. Huang Cong Yun, Shi Ximin and Du Zihong were elected as members of the remuneration and assessment committee of the 10th board of directors, and Huang Cong Yun was the chairman. The board of directors appointed Yu Jianhong as the general manager of the company and appointed Huang Jinlong.
2020
07-31
Peak natural products pollution control results by the industry attention
As a leader in China's plant extracts industry, Tianjin Jianfeng Natural Products Company has achieved fruitful results in technological innovation. On October 26 and 27, at the 2017 Forum on improving the international competitiveness of China's plant extract industry held in Handan City, Hebei Province, Liu Dan, general manager of the company, delivered a speech entitled "prevention and control of water pollution in the field of plant extraction", introducing the successful experience of sewage treatment in the past five years, which was widely concerned by the participants. In recent years, environmental protection and ecology have become hot words for the development of enterprises and society. Due to the particularity of the plant extraction industry, pollution control in this industry has different characteristics and requirements from ordinary production enterprises. For example, sewage presents higher chroma, extremely low PH value, more suspended solids, high salinity, high concentration of COD, and different sewage water quality of different products. As the earliest enterprise producing opc grape seed extract in China, Natural Products Company has always attached great importance to the pollution control of plant extraction. For example, in the sewage treatment upgrading project implemented in 2016, ozone oxidation and biochemical methods were adopted to remove the remaining organic pollutants, increasing the sewage treatment capacity from 200 cubic meters per day to 500 cubic meters. The latest anaerobic sewage treatment technology is adopted, the COD emission value of the outlet is reduced to 60 mg per liter, which is far lower than the national first-class emission standard of 100 mg per liter. The new system adopts advanced oxidation reaction tower, ozonation method, field energy reactor and sludge adsorption reflux technology, which can quickly and efficiently treat organic pollutants with strong chemical stability without adding any chemicals.
2020
07-31